Caxton Associates (New York)’s Inovio Pharmaceuticals INO Stock Holding History

Caxton Associates (New York)’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-65,390	Closed	-$643K	–	568
2023 Q1	$643K	Buy	65,390 +16,793	+35%	+$286K	0.1%	220
2022 Q4	$910K	Buy	48,597 +37,703	+346%	+$855K	0.06%	128
2022 Q3	$226K	Buy	+10,894	New	+$279K	0.03%	378

Other funds holding INO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Caxton Associates (New York)'s INO Position: Q2 2023 in Review

Caxton Associates (New York) sold out of Inovio Pharmaceuticals (INO) in Q2 2023, closing a stake of 65,390 shares — an estimated $643K sold.

Caxton Associates (New York) first reported a position in INO in Q3 2022 and held it in 3 quarters. The position peaked at $910K in Q4 2022. 133 funds tracked by Wall St. Rank hold INO as of Q2 2023.

Caxton Associates (New York) reported no remaining Inovio Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Caxton Associates (New York) sold 65,390 Inovio Pharmaceuticals shares in Q2 2023, an estimated $643K.
Caxton Associates (New York) first reported a position in Inovio Pharmaceuticals in Q3 2022 and held it in 3 quarters.
Caxton Associates (New York)'s Inovio Pharmaceuticals position peaked at $910K in Q4 2022.
133 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2023.

Based on Caxton Associates (New York)'s 13F filing for Q2 2023, filed 15 Aug 2023.